Lubomir B.
- Country
- Poland
- Department
- Oddział Onkologii Klinicznej i Radioterapii
Research Overview
- A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy
- A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
- Phase 3 Study Comparing Rinatabart Sesutecan Versus Investigator's Choice in Patients With Recurrent or Progressive Endometrial Cancer Following Platinum-Based and PD(L)-1 Therapy
Data & Insights
Has run more than one trial at 552 of 844 partner sites.
Specializations
Gynecologic Oncology
Specialized research in advanced female reproductive system cancers, with particular emphasis on innovative treatments for ovarian and endometrial malignancies.
- Platinum-resistant ovarian cancer therapy
- Advanced endometrial cancer treatments
- Fallopian tube and peritoneal cancers
Investigating targeted therapies and immunotherapy combinations for gynecologic malignancies.
Thoracic and Head/Neck Oncology
Focus on developing treatments for non-small cell lung cancer and head and neck squamous cell carcinoma.
- Locally advanced unresectable NSCLC
- Advanced head and neck cancer
- Post-chemoradiation therapy approaches
Evaluating novel immunotherapy combinations and targeted treatments in thoracic and head/neck cancers.
Skin Cancer and Melanoma
Expertise in treating advanced melanoma with innovative therapeutic approaches.
- Metastatic melanoma treatment
- High-risk resected melanoma
- Immunotherapy combinations
Investigating new treatment strategies for both early-stage and advanced melanoma cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.